PHARMOCANN GLOBAL LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103 ILa | 0.00% |
|
+3.00% | -26.48% |
| Mar. 31 | Pharmocann Global Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Pharmocann Global Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 22.66M 5.95M 2.27B | Sales 2023 | 14.41M 3.79M 1.44B | Capitalization | 3.12M 820K 312M |
|---|---|---|---|---|---|
| Net income 2022 | -25M -6.57M -2.5B | Net income 2023 | -9M -2.36M -900M | EV / Sales 2022 | 0.4 x |
| Net cash position 2022 | 925K 243K 92.5M | Net cash position 2023 | 768K 202K 76.8M | EV / Sales 2023 | 0.16 x |
| P/E ratio 2022 |
-0.26
x | P/E ratio 2023 |
-0.28
x | Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.05% |
More Fundamentals
* Assessed data
| 1 week | +3.00% | ||
| Current month | -40.05% | ||
| 1 month | -40.05% | ||
| 3 months | -45.79% | ||
| 6 months | -48.53% | ||
| Current year | -26.48% |
1 week
100.00
105.00
1 month
81.00221.00
Current year
51.10221.00
1 year
51.10305.00
3 years
51.1018 470.00
5 years
51.1036 990.00
10 years
51.1036 990.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 40 | 19-06-16 | |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 69 | 19-12-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guy Sigura
CHM | Chairman | 47 | 22-12-04 |
Locar Gila
BRD | Director/Board Member | 51 | 22-11-28 |
| Director/Board Member | 43 | 22-11-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 103 | +3.00% | 3,176 |
| 24-04-21 | 100 | -20.63% | 4,466 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotes
Medical Compression System DBN Ltd is an Israel-based company active in the medical sector. It is engaged in the research, development, production and marketing of non-invasive and non-medicinal solutions to improve the blood flow processes, using a pneumatic device which places pressure on the limbs by means of compressed air. The technology developed by the Company facilitates reducing the risk of blood clots forming during traumatic and surgical events, and secular diseases. It also completed the development of a pneumatic device for preventing the formation of blood clots in the deep veins system as the result of a trauma or surgical intervention, which is called the ActiveCare DVT.
| 1st Jan change | Capi. | |
|---|---|---|
| -26.48% | 661K | |
| +31.96% | 272M | |
| +33.74% | 261M | |
| +49.42% | 194M | |
| +44.98% | 131M | |
| -28.57% | 121M | |
| +115.91% | 119M | |
| 0.00% | 86.82M | |
| +150.00% | 75.33M | |
| +1.20% | 55.24M |
- Stock Market
- Equities
- PMCN-M Stock
